|
|
|
抗HER2/neu抗体的治疗效果取决于先天性免疫和获得性免疫 |
|
|
|
|
|
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity |
|
|
|
|
|
Park S Jiang Z Mortenson ED Deng L Radkevich-Brown O,Yang X ,Sattar H ,Wang Y ,Brown NK ,Greene M, Liu Y ,Tang J ,Wang S, Fu Y-X 2010/9/13 9:36:00 |
|
【发表评论】
|
|
|
|
打印|
推荐给好友
|
|
|
Cancer Cell, 2010, Volume 118, Issue 2
|
|
|
|
|
|
|
Anti-HER2/neu antibody therapy is reported to mediate tumor regression by interrupting oncogenic signals and/or inducing FcR-mediated cytotoxicity. Here, we demonstrate that the mechanisms of tumor regression by this therapy also require the adaptive immune response. Activation of innate immunity and T cells, initiated by antibody treatment, was necessary. Intriguingly, the addition of chemotherapeutic drugs, although capable of enhancing the reduction of tumor burden, could abrogate antibody-initiated immunity leading to decreased resistance to rechallenge or earlier relapse. Increased influx of both innate and adaptive immune cells into the tumor microenvironment by a selected immunotherapy further enhanced subsequent antibody-induced immunity, leading to increased tumor eradication and resistance to rechallenge. This study proposes a model and strategy for anti-HER2/neu antibody-mediated tumor clearance. © 2010 Elsevier Inc.
|
|
|
|
|
|
|
Correspondence Address: Wang, S; IBP-UC Group for Immunotherapy, CAS Key Laboratory for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing 100101, China, email:sdwang@moon.ibp.ac.cn |
|
|
|
|
|
|
|
|
|
|
请登录后发表评论,点击此处登录。
|
|
|
疾病资源中心
王燕燕 王曙
上海交通大学附属瑞金医院内分泌科
患者,女,69岁。2009年1月无明显诱因下出现乏力,当时程度较轻,未予以重视。2009年3月患者乏力症状加重,尿色逐渐加深,大便习惯改变,颜色变淡。4月18日入我院感染科治疗,诉轻度头晕、心慌,体重减轻10kg。无肝区疼痛,无发热,无腹痛、腹泻、腹胀、里急后重,无恶性、呕吐等。入院半月前于外院就诊,查肝功能:ALT 601IU/L,AST 785IU/L,TBIL 97.7umol/L,白蛋白 41g/L,甲状腺功能:游离T3 30.6pmol/L,游离T4 51.9pmol/L,心电图示快速房颤。
医学数据库
|